Abstract "Survival of the fi ttest" is an old axiom laid down by the great evolutionist Charles Darwin and microorganisms seem to have exploited this statement to a great extent. The ability of viruses to adapt themselves to the changing environment has made it possible to inhabit itself in this vast world for the past millions of years. Experts are well versed with the fact that infl uenza viruses have the capability to trade genetic components from one to the other within animal and human population. In mid April 2009, the Centers for Disease Control and Prevention and the World Health Organization had recognized a dramatic increase in number of infl uenza cases. These current 2009 infections were found to be caused by a new strain of infl uenza type A H1N1 virus which is a re-assortment of several strains of infl uenza viruses commonly infecting human, avian, and swine population. This evolution is quite dependent on swine population which acts as a main reservoir for the reassortment event in virus. With the current rate of progress and the efforts of heath authorities worldwide, we have still not lost the race against fi ghting this virus. This article gives an insight to the probable source of origin and the evolutionary progress it has gone through that makes it a potential threat in the future, the current scenario and the possible measures that may be explored to further strengthen the war against pandemic.
Introduction
Infl uenza A virus, which belongs to the Orthomyxoviridae family of RNA viruses, mutate more rapidly showing more antigenic fl exibility and hence are more virulent as compared to the other two subtypes of infl uenza virus (B and C) [1, 2] . It has been responsible for widescale pandemics since the 16th century causing at least 31 pandemics in the past 400 years [3] . The world had seen three major pandemics that have occurred in the 20th century, marked as the Spanish fl u in 1918, Asian fl u in 1957 and Hong Kong fl u in 1968-69 leading to a large death toll [4] [5] [6] . Adding to this number is the novel swine (H1N1) 2009 virus recently spread globally with unprecedented speed that the World Health Organisation (WHO) raised its pandemic alert phase from Phase 3 to Phase 4 on 27 April 2009 and from Phase 4 to Phase 5 on 29 April 2009. On 11 June 2009 the pandemic level was escalated further from phase 5 to 6, which has made the health authorities conscious of its future potentials as the killer fl u [6] . The attack rates for this A (H1N1) pandemic strain are expected to be higher than for seasonal strains because of the lower levels of pre-existing immunity in the population. Often, these new strains appear when an existing fl u virus spreads to humans from other animal species, or when an existing human strain picks up new genes from a virus that usually infects birds. The sudden ability of this new swine fl u virus to jump from pigs to humans and then to have sustained human to human transmission is an excellent example of evolution at work.
Being reported for the fi rst time in United States and Mexico in March-April 2009, pandemic infl uenza H1N1 has emerged as deadly and virulent form of swine infl uenza virus that has infected human population at an alarmingly high rate showing a sustained global pattern of human transmission [7, 8] 
Origin of infl uenza A (H1N1) virus
Genetic reassortment is one of the major reasons for a pandemic outbreak and occurs when genes from different species viz. human, avian and swine come together and are able to infect different host [11] . The rapid evolution of the infl uenza virus is an excellent example of natural selection. Infl uenza virus deserves particular attention as it undergoes a high rate of antigenic change giving rise to a new type of infl uenza strain for which there is no immunity in the population. H1N1 infl uenza A virus has persisted for more than 90 years since the 1918 pandemic. It is quite remarkable that the descendents of 1918 virus still circulate in humans as epidemic H1N1 and and in swine as epizootic H1N1 causing new pandemics, epidemics and epizootics. The novel H1N1 virus of the 2009 is the fourth generation descendent of the 1918 virus (Table 1 ) [12] .
The genetic make-up of the novel 2009 H1N1 infl uenza A virus is that of a reassortant form which is constituted of gene segments from the swine, avian and human fl u virus genes that does not share much similarity with the earlier known swine viruses. The current novel H1N1 virus shows it is a "quadruple reassortant" virus having 2 genes of Eurasian origin and 6 genes of North American origin which has infected the swine population. It is a reassortant with three potential host source with HA, NA, MP, NP and NS originating from swine infl uenza virus, PB2 and PA originating from bird infl uenza virus and PB1 from human infl uenza virus (fi gure 1) [13, 14] .
Mutational changes in pandemic H1N1 infl uenza virus
The applicability of comparative sequence analysis technique for the molecular determinants of virulence in viruses has a profound effect on recent viewing in systematics and evolution of the virus. This type of molecular screening and phylogenetic assessment helps in understanding evolution of infl uenza viruses and for the early detection of emerging novel viruses which can lead to infl uenza pandemics. The emphasis on the seasonal infl uenza strains have recently been suppressed by emergence of even more virulent swine infl uenza virus 2009 (H1N1) strain. To gain an insight into the possible origin of 2009 outbreak of new infl uenza A (H1N1), protein homology and phylogenetic analysis has been used to study the sequence of proteins encoded by PB1, PB2, PA, HA, NP, MP1 and NS1 of the new H1N1 virus. These [11] studies revealed that the virus has most likely evolved from recent swine viruses and that the new infl uenza A (H1N1) virus possesses a distinctive evolutionary trait to the infl uenza A viruses circulating in North America for the last two decades (1989-2009). These analyses also contribute to the role of pig population as the mixing vessels for infl uenza H1N1 viruses. Looking in detail of some of the important genes of the virus, studies reveal the HA and the NA gene of the recent swine H1N1 virus, both coding for the surface antigens, has undergone a change. The HA gene has acquired a proline to serine substitution at position 200 thus has become slightly less virulent as compared to the 1918 (H1N1) virus. The NA gene, is also quite novel differing by 18.2% from the seasonal H1N1 virus which may be a possible reason that the available vaccines may not work effectively against the virus thereby increasing the demand for newly formulated vaccines in a short period of time [15, 16] .
NS1 protein, the non-structural protein encoded by the NS gene is also truncated by stop codon at position 220 hereby creating a deletion in the PDZ domain involved in variety of cell signaling pathways as evident in 1918 H1N1 and H5N1 fl u viruses [17] .One of the other important genes PB1-F2, associated with the pathogenicity of 1918 pandemic virus and H5N1, has been found to be truncated with a stop codon at three positions of 12, 55 and 88 indicating that further genetic analysis study is required to fully associate this gene functionality to the virulence of this novel H1N1 virus [18] .
Antiviral and vaccination strategy
The clinical manifestations of the current 2009 infl uenza A (H1N1) virus are quite similar to the seasonal infl uenza virus, that makes it very diffi cult to differentially diagnose the swine H1N1 infection from the seasonal one, if precise and reliable molecular tests such as the real time PCR are not used. The incubation period of seasonal infl uenza in human is generally 1-4 days, with an average of 2 days which is similar for swine H1N1 except that few patients experience a sudden and rapid deterioration in their clinical condition, usually on day 5 or 6 following the onset of symptoms [19] .
The new infl uenza A (H1N1) are currently susceptible to neuraminidase inhibitors such as oseltamivir (Tamifl u) and zanamivir (Relenza), but are found to be resistant to M2 inhibitors such as Amantadine and Rimantidine [20] . Use of the present available antiviral drugs for prophylaxis is also not recommended, since in many countries viz. Japan, Denmark, and Hong Kong, till now, 21 cases of oseltamivir resistance have been reported . The mutation in NA gene of the new virus, shows that the antiviral drug, Tamifl u (oseltamivir), may not be able to control the virus effectively and further enhance the possibility of generation of drug resistant viruses as seen in some countries [15] .
Vaccination with a strain-specifi c pandemic vaccine is considered to be one of the most effective measures for protecting individuals in the event of a pandemic. Thus, vaccines are considered to be the best approach towards preventing spread of the swine infl uenza infection. The new vaccine candidate for the 2009 pandemic infl uenza A has been infl uenza A /California /7 /2009, that is being produced as an inactivated surface antigen, since the existing sequences of 2009 infl uenza A are similar to this strain. Vaccine development against the current virus has started with the use of adjuvant for which trials have been started with M59 adjuvant and non-adjuvant forms [21] . In India also, three pharmaceutical companies, Serum Institute of India, Bharat Biotech, Hyderabad and Panacea Biotec, New Delhi have joined in the race for development of vaccine and are working diligently on its development [22] Since, this novel swine H1N1 is highly unpredictable at this point of time, and it is pretty diffi cult to forecast about its pathogenicity well in advance. The virus may lose its virulence or even become more virulent in its second wave. It may acquire spontaneous mutations which may make it more pathogenic or the virus may even swap genes with the highly pathogenic avian infl uenza virus (H5N1) through gene re-assortment and lead to a formation of even deadlier strain capable of sustained human to human transmission. If these events continue to occur in the second wave, the impact of the virus may become more severe depending on the population density, and the ability of the virus to mutate and take even more virulent forms.
Presently, the Global Infl uenza Surveillance System of WHO is built upon a network of 112 national infl uenza centres in 83 countries working closely together with its four WHO collaborating centres. By participating in the Global Infl uenza Surveillance Network, a country can effectively contribute to information regarding the pandemic situation globally [23] .
The recent pandemic alert indicates that it is time to take stringent action towards the establishment of a strong and systemic surveillance system that will integrate phylogenetic information of infl uenza in human and livestock. The reassortment events in mammals often lead to the generation of pandemic infl uenza strains over a period of years and hence it is suggested that appropriate surveillance strategies should be developed for detection of precursor viruses that could help in aborting the future pandemic wave.
